The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of a subcutaneous formulation of Sarclisa (isatuximab) for patients with multiple myeloma. If authorized, this treatment would become the first anti-cancer therapy administered via an on-body injector, providing patients with the flexibility of both manual and device-assisted injections.
What is the significance of the Sarclisa subcutaneous formulation?
The CHMP recommendation, announced on March 27, 2026, is based on clinical data demonstrating that subcutaneous Sarclisa maintains comparable efficacy, safety, and pharmacokinetics to the existing intravenous (IV) version of the drug. According to Sanofi, the new formulation aims to offer patients greater convenience by allowing administration through an on-body injector (OBI) or manual injection. This flexibility is designed to support care in both home and ambulatory settings, potentially reducing the burden on healthcare systems.
How does this treatment work for multiple myeloma?
Multiple myeloma is a cancer of the plasma cells, where abnormal cells accumulate in the bone marrow and interfere with healthy cell function. Sarclisa is an anti-CD38 monoclonal antibody. Since its initial introduction in 2020, it has been used to treat patients across nearly 60 countries. The subcutaneous option is intended for use in combination with current standard therapeutic regimens for all indications currently approved for the IV formulation in the European Union.
What is the current status of global regulatory reviews?
While the CHMP has provided a favorable opinion for the EU, regulatory reviews remain ongoing in other major markets. Sanofi has confirmed that the subcutaneous formulation is currently under assessment by health authorities in the United States, Japan, and China.
Key Takeaways
- Regulatory Progress: The CHMP recommended the approval of subcutaneous Sarclisa in the EU on March 27, 2026.
- Technological Innovation: If approved, it will be the first cancer treatment available with both an on-body injector and a manual injection option.
- Clinical Basis: The recommendation relies on data showing the subcutaneous method is comparable to the established intravenous version in terms of safety and efficacy.
- Global Reach: The treatment is currently under review in the U.S., Japan, and China, with a final decision in the EU expected in the coming months.
Looking Ahead
The shift toward subcutaneous administration represents an ongoing effort by pharmaceutical developers to modernize oncology care. By moving away from traditional IV infusions, which often require lengthy clinical stays, this approach prioritizes patient autonomy. As regulatory agencies in the U.S. and other regions complete their evaluations, the medical community will continue to monitor how these delivery methods impact long-term patient outcomes and treatment adherence in multiple myeloma care.